Home Southeast Miami, FL Noven Pharmaceuticals COMPANY
Status: Acquired, now part of Hisamitsu Pharmaceutical · How status works
Clinical Phase 3
16 open jobs · last seen Oct 23, 2026 · 6 sources
Keywords: psychiatry women's health drug delivery transdermal Osteoarthritis of the Knee Osteoarthritis Pain of the Knee Attention Deficit Hyperactivity Disorder Cumulative Irritation and Sensitization Schizophrenia HP-5000 HP-1050 Show all 11 keywords
Profile checked Oct 10, 2026
At a glance Region Southeast Stage Clinical Phase 3 Latest trial Phase 1: Irritation and Sensitization Study of HP-5000 Topical System (Jun 3, 2021) source Timeline Jun 3, 2021 Trial start Phase 1: Irritation and Sensitization Study of HP-5000 Topical System source ↗ Dec 29, 2020 Trial start Phase 3: A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the Knee source ↗ Nov 3, 2020 Trial start Phase 1: Study Will Assess Skin Irritation and Sensitization for HP-1050 Patch source ↗ Sep 7, 2017 Trial start Phase 2: A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis source ↗ 2016-08 Trial start Phase 3: Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia. source ↗ 2012-10 Trial start Phase 2: Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System vs Placebo in Children & Adolescents With ADHD source ↗ Clinical trials (lead sponsor) 6 Record Title Phase Status Start Primary completion NCT04683627 A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the Knee Phase 3 Completed Dec 29, 2020 Jul 18, 2022 (actual) NCT01711021 Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System vs Placebo in Children & Adolescents With ADHD Phase 2 Completed 2012-10 2013-03 (actual) NCT04882319 Irritation and Sensitization Study of HP-5000 Topical System Phase 1 Completed Jun 3, 2021 Mar 8, 2022 (actual) NCT03277066 A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis Phase 2 Completed Sep 7, 2017 Sep 25, 2019 (actual) NCT04624867 Study Will Assess Skin Irritation and Sensitization for HP-1050 Patch Phase 1 Unknown status (ClinicalTrials.gov) Nov 3, 2020 Jan 31, 2022 (estimated) NCT02876900 Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia. Phase 3 Completed 2016-08 2018-06 (actual)
Open jobs 16 Title Location (from posting, not HQ) Employer posted First seen Level Mfg Operator BC - TEMP US-FL-Miami Not stated Oct 20, 2026 Not stated Mfg Operator BC - TEMP US-FL-Miami Not stated Oct 17, 2026 Not stated Mfg Operator BC - TEMP US-FL-Miami Not stated Oct 16, 2026 Entry Description Mfg Operator BC - TEMP US-FL-Miami Not stated Oct 16, 2026 Mid Description Mfg Operator BC US-FL-Miami Not stated Oct 16, 2026 Mid Description QA Inspector US-FL-Miami Not stated Oct 16, 2026 Mid Description Quality Specialist US-FL-Miami Not stated Oct 16, 2026 Mid Description Laboratory Technician III US-FL-Miami Not stated Oct 16, 2026 Mid Description Assoc Director Reg Affairs US-NJ-Jersey City Not stated Oct 16, 2026 Senior Description Service Desk Analyst US-FL-Miami Not stated Oct 16, 2026 Mid Description Service Desk Analyst US-FL-Miami Not stated Oct 16, 2026 Mid Description Mfg Operator PC - TEMP US-FL-Miami Not stated Oct 16, 2026 Mid Description QA Inspector - TEMP US-FL-Miami Not stated Oct 16, 2026 Mid Description Technician II - TEMP US-FL-Miami Not stated Oct 16, 2026 Mid Description QA Inspector - TEMP US-FL-Miami Not stated Oct 16, 2026 Mid Description Director Clinical Pharmacology US-NJ-Jersey City Not stated Oct 16, 2026 Senior Description
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
Connect See your connections at Noven Pharmaceuticals on LinkedIn (search by name, results not checked) LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.
LinkedIn page linked from the company's own site: source · seen 2026-10-18
